COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers.
作者信息
Bakasis Athanasios-Dimitrios, Moutsopoulos Haralampos M
机构信息
Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Academy of Athens, Athens, Greece.
出版信息
Mediterr J Rheumatol. 2021 Sep 6;32(3):188-191. doi: 10.31138/mjr.32.3.188. eCollection 2021 Sep.
Abstract
摘要
相似文献
1
COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers.2019冠状病毒病与自身免疫性/自身炎症性风湿性疾病患者：经验教训与有待解答的问题
Mediterr J Rheumatol. 2021 Sep 6;32(3):188-191. doi: 10.31138/mjr.32.3.188. eCollection 2021 Sep.
2
A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.接种疫苗（包括 COVID-19 疫苗）在自身免疫/炎症性风湿病中的实用方法：非系统性综述。
Clin Rheumatol. 2021 Sep;40(9):3533-3545. doi: 10.1007/s10067-021-05700-z. Epub 2021 Mar 22.
3
Epigenetics for Clinicians from the Perspective of Pediatric Rheumatic Diseases.从儿科风湿病学角度看临床医生的表观遗传学
Curr Rheumatol Rep. 2020 Jul 11;22(8):46. doi: 10.1007/s11926-020-00912-9.
4
Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020.管理 COVID-19 大流行期间的风湿性疾病患者：法国风湿病学会回答了截至 2020 年 5 月最常被问到的问题。
Joint Bone Spine. 2020 Oct;87(5):431-437. doi: 10.1016/j.jbspin.2020.05.006. Epub 2020 May 27.
5
Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.成人 COVID-19 相关的自身免疫和风湿表现：一项更新的系统评价。
Front Immunol. 2021 Mar 12;12:645013. doi: 10.3389/fimmu.2021.645013. eCollection 2021.
6
Perception of self: distinguishing autoimmunity from autoinflammation.自我感知：区分自身免疫与自身炎症。
Nat Rev Rheumatol. 2015 Aug;11(8):483-92. doi: 10.1038/nrrheum.2015.60. Epub 2015 May 12.
7
Mutations/polymorphisms in a monogenetic autoinflammatory disease may be susceptibility markers for certain rheumatic diseases: lessons from the bedside for the benchside.单基因自身炎症性疾病中的突变/多态性可能是某些风湿性疾病的易感标志物：从床边到实验台的经验教训。
Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S29-31.
8
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.儿科风湿性和自身炎症性疾病结局指标的当前研究
Curr Rheumatol Rep. 2016 Feb;18(2):8. doi: 10.1007/s11926-015-0558-4.
9
Role of vaccinations and prophylaxis in rheumatic diseases.疫苗接种和预防在风湿性疾病中的作用。
Best Pract Res Clin Rheumatol. 2015 Apr;29(2):306-18. doi: 10.1016/j.berh.2015.02.001. Epub 2015 Apr 2.
10
Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases.伴发自身免疫/炎症性疾病的泛发性白癜风患者的临床特征。
J Eur Acad Dermatol Venereol. 2014 Jun;28(6):741-6. doi: 10.1111/jdv.12169. Epub 2013 Apr 17.
引用本文的文献
1
Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.奥密克戎变异株的流行和抗 SARS-CoV-2 疫苗接种是系统性自身免疫性风湿病患者 COVID-19 轻症化的关键决定因素。
Clin Rheumatol. 2023 Dec;42(12):3375-3385. doi: 10.1007/s10067-023-06769-4. Epub 2023 Sep 21.
2
Clinical Features and Outcomes of Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease and Spondyloarthropathies.炎症性肠病和脊柱关节炎患者 2019 年冠状病毒病的临床特征和结局。
Turk J Gastroenterol. 2022 Sep;33(9):751-759. doi: 10.5152/tjg.2022.22181.
本文引用的文献
1
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.腺病毒载体新冠疫苗和 mRNA 新冠疫苗序贯和同源加强接种的安全性和免疫原性比较（Com-COV）：一项单盲、随机、非劣效性试验。
Lancet. 2021 Sep 4;398(10303):856-869. doi: 10.1016/S0140-6736(21)01694-9. Epub 2021 Aug 6.
2
COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review.COVID-19 感染在自身免疫性风湿病患者中的情况：来自观察性研究和文献复习的数据。
J Autoimmun. 2021 Sep;123:102687. doi: 10.1016/j.jaut.2021.102687. Epub 2021 Jul 16.
3
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.BNT162b2 mRNA COVID-19 疫苗在成年自身免疫性炎症性风湿病患者和普通人群中的免疫原性和安全性：一项多中心研究。
Ann Rheum Dis. 2021 Oct;80(10):1330-1338. doi: 10.1136/annrheumdis-2021-220647. Epub 2021 Jun 14.
4
A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine.推荐的风湿性疾病患者接种 SARS-CoV-2 疫苗的模式。
J Autoimmun. 2021 Jul;121:102649. doi: 10.1016/j.jaut.2021.102649. Epub 2021 May 1.
5
6
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者 COVID-19 相关死亡的相关因素：来自 COVID-19 全球风湿病联盟医生报告登记处的结果。
Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.
7
Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.通过I/III型干扰素的时间模式及流感对比揭示的新冠病毒感染中失调的抗病毒免疫
Nat Immunol. 2021 Jan;22(1):32-40. doi: 10.1038/s41590-020-00840-x. Epub 2020 Dec 4.
8
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
9
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients.COVID-19 严重程度与风湿和炎症性疾病患者的生存：来自法国 RMD COVID-19 队列的 694 例患者的数据。
Ann Rheum Dis. 2021 Apr;80(4):527-538. doi: 10.1136/annrheumdis-2020-218310. Epub 2020 Dec 2.
10
Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?用于抗击新型冠状病毒感染（SARS-CoV-2）的抗风湿药物：有哪些证据？
Mediterr J Rheumatol. 2020 Sep 21;31(Suppl 2):259-267. doi: 10.31138/mjr.31.3.259. eCollection 2020 Sep.
Zotero 插件